AstraZeneca PLC (AZNCF)
| Market Cap | 260.83B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.31 |
| PE Ratio | 31.44 |
| Forward PE | 17.26 |
| Dividend | 3.13 (1.83%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,000 |
| Average Volume | 3,627 |
| Open | 167.00 |
| Previous Close | 169.12 |
| Day's Range | 167.00 - 167.00 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.17 |
| RSI | 63.30 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca's Datroway extends survival in aggressive breast cancer
AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for...
AstraZeneca : ENHERTU Shows Significant Survival Benefit In DESTINY-Breast05 Phase III Trial
(RTTNews) - AstraZeneca announced that the Phase III DESTINY-Breast05 trial demonstrated ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improves invasive disease-free survival (IDFS) in patie...
AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials
AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.
Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation
(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment for inadequately control...
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.
AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis
AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis
Amgen, AstraZeneca gets FDA nod for Tezspire
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years ...
US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.
AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects
AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects
Astra, GSK up after report on U.K. – U.S. drug pricing deal
AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.
AstraZeneca (AZN) Gains EU Backing for New Lupus Treatment
AstraZeneca (AZN) Gains EU Backing for New Lupus Treatment
AstraZeneca's Imfinzi Improves Disease-Free Survival In Early-Stage Bladder Cancer
(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durvalumab to standard BCG therapy significan...
SPDW, ASML, SAP, AZN: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI
AstraZeneca's (AZN) IMFINZI Shows Promising Results in Bladder Cancer Trial
AstraZeneca's (AZN) IMFINZI Shows Promising Results in Bladder Cancer Trial
AstraZeneca reports positive data from Imfinzi's bladder cancer trial
AstraZeneca (AZN) Lung Cancer Trial Highlights New Diagnostic Tool
AstraZeneca (AZN) Lung Cancer Trial Highlights New Diagnostic Tool
AstraZeneca (AZN): Lynparza's Role in Ovarian Cancer Treatment
AstraZeneca (AZN): Lynparza's Role in Ovarian Cancer Treatment
AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Production
AstraZeneca (AZN) Expands Coppell Facility to Boost Lokelma Production
AstraZeneca unveils expanded manufacturing facility in Texas
COPPELL, Texas--(BUSINESS WIRE)--AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the produ...
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.